BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 8 July, 2014 at 9.10 a.m. Biotie: Tozadenant Phase 2b Parkinson` s disease study published in Lancet Neurology...
From dance groups for people with Parkinson' s disease to tactile art installations by the visually impaired, a new inclusive cultural program is putting the arts in the hands of...
Cynapsus Therapeutics Inc. , a specialty pharmaceutical company focused on Parkinson' s disease, today announced that following communication from the United States Food and Drug...
Research and Markets has announced the addition of the "Parkinson's Disease Pipeline Highlights - 2014 Update" report
Title: Brisk Walking May Help Curb Parkinson's Symptoms Category: Health News Created: 7/2/2014 4:35:00 PM Last Editorial Review: 7/3/2014 12:00:00 AM
Cynapsus Therapeutics Inc : Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the United States
July 17 2014 TORONTO, CANADA - Cynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company focused on Parkinson` s disease, today announced that...
Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for...
Parkinson's disease is the second most common neurological disorder, affecting almost 10 million people worldwide.
( American Friends of Tel Aviv University ) Tel Aviv University has conducted the first empirical study to verify a link between Parkinson' s disease and artistic inclination. The...